US FDA Modernization Act, Section 114: Uses, Opportunities and Implications for Comparative Effectiveness Research

Author： Neumann Peter J.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.8, 2011-08, pp. : 687-692

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Swimming Upstream: Comparative Effectiveness Research in the US

By Greene Jeremy A.  

PharmacoEconomics, Vol. 27, Iss. 12, 2009-12 ,pp. : 979-982

Adis International

Access to resources Recommend Favorite

Comparative effectiveness research: what future in the US?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 583, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

International Comparison of Comparative Effectiveness Research in Five Jurisdictions: Insights for the US

By Levy Adrian R.   Mitton Craig  

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 813-830

Adis International

Access to resources Recommend Favorite

The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and their Implications for Prioritizing Public Investments in Comparative Effectiveness Research

By Meltzer David  

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 843-853

Adis International

Access to resources Recommend Favorite

The US Congress has passed the FDA Amendments Act of 2007

By  

Reactions Weekly, Vol. 1, Iss. 1171, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite